BPH treatment market value to reach nearly $5 bn by 2024

The value of the global therapeutics market for Benign Prostatic Hyperplasia (BPH) will rise from just over $2 billion in 2014 to approximately $4.9 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 8.23%


(Photo Courtesy: www.stratacloud.com)

According to research and consulting firm, GlobalData, the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, the US will continue its current dominance, accounting for 65% of the global arena by 2024.

Dr Valentina Gburcik, GlobalData's director of cardiovascular & metabolic disorders, states that three novel therapies will contribute to the growth of the BPH therapeutics market, including the launch of Nymox's novel first-in-class therapy, NX-1207, in the US and Europe in 2017 and 2019, respectively.

She says: "NX-1207 is a direct prostatic injection indicated for patients with moderate-to-severe BPH. It offers an increased safety profile and improved efficacy in comparison with currently available BPH therapies, and lasts for a mean duration of 3.5 years after a single injection.

"The drug will also be priced at a premium compared with current products, meaning that it will contribute significantly towards the anticipated market expansion following its launch."

She adds that an increasing number of diagnosed BPH cases worldwide, resulting from an aging male population, will further drive the market over the forecast period.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email